5 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Lewy body dementia, Nutritional and Metabolic Diseases, amyloidosis, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, proteostasis deficiencies, psychiatric disorder, synucleinopathy, tauopathyRecruitingPhase 22026-10-08NCT07589595
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's DiseaseParkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathyRecruitingPhase 22026-10-02NCT06680830
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisLewy Body Dementia PsychosisRecruitingPhase 32026-09-29NCT07095465
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisLewy Body Dementia PsychosisRecruitingPhase 22026-09-29NCT07029581
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeAlzheimer's Disease Dementia; Mild Cognitive Impairment Due to Alzheimer's DiseaseActive, not recruitingPhase 22026-06-30NCT05399888